ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Lonza adds fill and finish in a deal with Novartis

by Rick Mullin
July 4, 2019 | APPEARED IN VOLUME 97, ISSUE 27

 

Lonza will enter the sterile drug fill-and-finish business by acquiring a Novartis facility in Stein, Switzerland. The facility includes liquid and lyophilized dosage-form capacity for clinical and commercial supply. Lonza will produce for Novartis and for third parties. The deal continues a trend among pharmaceutical services firms to build up finished-drug manufacturing capacity. Last month Catalent said it will acquire Bristol-Myers Squibb’s solid, biologics, and sterile product facility in Anagni, Italy.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment